SML3476
Brivaracetam
≥98% (HPLC)
别名:
(αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide, (2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide, (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, UCB 34714, UCB-34714, UCB34714
质量水平
方案
≥98% (HPLC)
表单
powder
药品控制
USDEA Schedule V
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
-10 to -25°C
正在寻找类似产品? 访问 产品对比指南
相关类别
生化/生理作用
Brivaracetam shows approximately 10 times greater potency than levetiracetam (Keppra)*; pIC50 at LBS = 7.0; inhibits audiogenic seizures in seizure-prone mice (ED50 = 14 μmol/kg) and is also effective in other animal models of epilepsy. Brivaracetam is used as an anticonvulsant (antiepileptic) for seizure treatment.
Orally active levetiracetam analog with higher synaptic vesicle protein 2A (SV2A) affinity and >10 times greater in vivo antiseizure efficay.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Brivaracetam attenuates pain behaviors in a murine model of neuropathic pain
Molecular Pain (2019)
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity
Journal of medicinal chemistry, 47(3), 530-549 (2004)
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus
Journal of neural transmission (Vienna, Austria : 1996), 114(12), 1547-1551 (2007)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持